Harbin Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing, wholesale and retail of pharmaceutical. The Company is mainly engaged in two businesses. The pharmaceutical industry business is mainly engaged in the research, development and manufacturing of chemical raw materials, chemical preparations, biological preparations, traditional Chinese medicine and health care products. The pharmaceutical commercial business is mainly engaged in pharmaceutical commercial wholesale business and pharmaceutical commercial retail business. The Company's products mainly include zinc gluconate oral solution, calcium iron zinc oral solution, compound calcium gluconate oral solution, amoxicillin capsules and Shuanghuanglian oral solution. The Company's products are mainly used in digestive, respiratory, anti-infectious, cardiovascular and cerebrovascular and anti-tumor treatment fields.

Employees

10,039

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	CN¥3.140	+0.96%	47,919,283
26-07-02	CN¥3.110	+0.65%	55,241,229
26-07-01	CN¥3.090	+3.34%	56,432,732
26-06-30	CN¥2.990	-2.92%	52,907,866
26-06-29	CN¥3.080	+5.12%	72,354,928

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.140CNY

Average target price

4.310CNY

Spread / Average Target

+37.26%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2026-07-03			5-day change	1st Jan Change
3.140 ^CNY	+0.96%		+7.17%	-8.99%

04-22	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	7.91B 1.17B 1.02B 936M 872M 1.65B 111B 1.68B 11.24B 4.37B 54.53B 4.37B 4.28B 188B	P/E 2026 *	17.4x	P/E 2027 *	15x
Enterprise Value	7.91B 1.17B 1.02B 936M 872M 1.65B 111B 1.68B 11.24B 4.37B 54.53B 4.37B 4.28B 188B	EV / Sales 2026 *	0.48x	EV / Sales 2027 *	0.47x
Free-Float	47.74%	Yield 2026 *	-	Yield 2027 *	-

04-22	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-11	Harbin Pharmaceutical's Antibiotic Passes China's Generic Drug Evaluation	MT
02-06	Harbin Pharmaceutical's Unit Gets Nod to Market Ferric Protein Succinylate API	MT
02-05	Harbin Pharmaceutical's Two Antibiotics Pass China's Generic Drug Consistency Evaluation	MT
02-03	Harbin Pharmaceutical Gets Regulatory Nod for Anemia Drug	MT
11-20	Harbin Pharmaceutical Plans to Sell 1% Stake in People's Same Medicine	MT
25-10-24	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-21	Harbin Pharmaceutical's Subsidiary Gets Nod to Market Calcium Lactate API	MT
25-10-21	Harbin Pharmaceutical's Unit Gets Nod for Influenza Drug	MT
25-09-12	China Approves Harbin Pharmaceutical's Antihypertensive Drug	MT
25-08-22	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-05	Harbin Pharmaceutical to Lease Branch's Idle Property	MT

1 day	+0.96%
1 week	+7.17%
Current month	+5.02%
1 month	-0.95%
3 months	-10.80%
6 months	-8.99%
Current year	-8.99%

Harbin Pharmaceutical Group Co., Ltd. Stock

Stocks

600664

CNE0000009T3

Pharmaceuticals

Valuation: Harbin Pharmaceutical Group Co., Ltd.

Chart: Harbin Pharmaceutical Group Co., Ltd.

Latest news : Harbin Pharmaceutical Group Co., Ltd.

Press Releases: Harbin Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Harbin Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 week	2.84	3.18
1 month	2.84	3.28
Current year	2.84	4.88
1 year	2.84	4.88
3 years	2.41	4.97
5 years	2.41	4.97
10 years	2.38	9.77

Manager	Title	Age	Since
Chuan You Lu CEO	Chief Executive Officer	64	2023-12-26
Xiao Dong Meng DFI	Director of Finance/CFO	54	2004-12-23
Kun Yu Ma IRC	Investor Relations Contact	45	2022-04-26

Director	Title	Age	Since
Ai Dong Lou BRD	Director/Board Member	60	2020-11-30
Zhao Hua Li BRD	Director/Board Member	60	2021-01-07
Xiao Ping Hu CHM	Chairman	56	2023-12-26

Date	Insider	Type	Quantity	% Market Cap.
24-06-30	Bo Liu	Sell	150,000	0.0060%
24-06-30	Bangdong Li	Sell	27,000	0.0011%
24-06-30	Jicheng Xia	Sell	27,000	0.0011%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HARBIN PHARMACEUTICAL GROUP CO., LTD.	+0.96%	+7.17%	-18.23%	-4.56%	1.17B
ELI LILLY AND COMPANY	+1.86%	+0.48%	+55.50%	+163.08%	1,082B
JOHNSON & JOHNSON	+3.57%	+3.29%	+68.60%	+61.03%	633B
ABBVIE INC.	+3.99%	+3.05%	+37.93%	+93.37%	461B
ROCHE HOLDING AG	+3.86%	+1.64%	+31.35%	+24.29%	338B
ASTRAZENECA PLC	-0.56%	+0.96%	+39.86%	+36.64%	299B
NOVARTIS AG	-0.08%	+1.30%	+30.37%	+44.02%	291B
NOVO NORDISK A/S	-1.54%	+2.81%	-27.56%	-39.45%	222B
AMGEN INC.	+3.55%	+4.41%	+25.45%	+66.28%	202B
GILEAD SCIENCES, INC.	+4.21%	+2.65%	+17.47%	+71.11%	163B
Average	+1.98%	+4.31%	+26.07%	+51.58%	369.36B
Weighted average by Cap.	+2.24%	+5.53%	+41.76%	+82.98%

	2026 *	2027 *
Net sales	16.4B 2.42B 2.11B 1.94B 1.81B 3.43B 230B 3.48B 23.31B 9.06B 113B 9.07B 8.88B 390B	16.94B 2.5B 2.18B 2B 1.87B 3.54B 238B 3.6B 24.07B 9.36B 117B 9.37B 9.17B 402B
Net income	452M 66.6M 58.23M 53.51M 49.88M 94.6M 6.34B 96.04M 642M 250M 3.12B 250M 245M 10.74B	520M 76.67M 67.02M 61.59M 57.41M 109M 7.3B 111M 739M 287M 3.59B 288M 282M 12.36B
Net Debt	-	-